Panacos Pharmaceuticals, Inc. engages in the discovery and development of small-molecule oral drug which is designed to treat human immunodeficiency virus and other major human viral diseases. The company is headquartered in Watertown, Massachusetts and currently employs 41 full-time employees. The firm's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The firm has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Follow-Up Questions
Panacos Pharmaceuticals Inc (PANC) の株価収益率はいくらですか？
Panacos Pharmaceuticals Inc の株価収益率は 0 です。
Panacos Pharmaceuticals Inc のCEOは誰ですか？
Dr. Alan Dunton は Panacos Pharmaceuticals Inc の President で、2007 から在籍しています。
PANC の株価パフォーマンスは？
PANC の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Panacos Pharmaceuticals Inc の主な事業テーマや業界は？
Panacos Pharmaceuticals Inc は Biotechnology 業界、セクターは Health Care に属しています。
